The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia is a PHASE1 clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Relapsed Adult AML, Refractory AML. SEO and diligence focus: anti-CLL-1 CAR NK cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.